ProMIS Neurosciences Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Neil K. Warma

Chief Executive Officer (CEO)

US$40.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Neil K. Warma (61 yo)

less than a year

Permanencia

US$40,000

Compensación

Mr. Neil K. Warma, MBA, serves as Chief Executive Officer and President of ProMIS Neurosciences, Inc. from August 1, 2024 and has been its Director since December 30, 2023 and was its Interim Chief Executi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 164.6k
Neil K. Warma	CEO, President & Director	less than a year	US$40.00k	sin datos
Neil Cashman	Co-Founder	20.5yrs	US$378.82k	0.57% $ 118.3k
Gavin Malenfant	Chief Operating Officer	3.1yrs	US$435.90k	0.013% $ 2.7k
Daniel Geffken	Chief Financial Officer	7.7yrs	US$142.40k	0.029% $ 6.0k
Johanne Kaplan	Chief Development Officer	8.3yrs	US$525.57k	0.024% $ 5.0k
David Wishart	Chief Physics Officer	3.5yrs	sin datos	sin datos
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	sin datos	sin datos
Larry Altstiel	Chief Medical Officer	2.6yrs	sin datos	sin datos

3.5yrs

Permanencia media

65yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PMN se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 164.6k
Neil K. Warma	CEO, President & Director	3.5yrs	US$40.00k	sin datos
Neil Cashman	Co-Founder	17.8yrs	US$378.82k	0.57% $ 118.3k
William Wyman	Independent Director	10.7yrs	US$40.00k	0.31% $ 64.8k
William Mobley	Member of Scientific Advisory Board	7.4yrs	sin datos	sin datos
Patrick Kirwin	Independent Director	9.4yrs	US$40.00k	0.49% $ 102.0k
Joshua Mandel-Brehm	Independent Director	3.2yrs	US$40.00k	0% $ 0
Sharon Cohen	Member of Scientific Advisory Board	6.7yrs	sin datos	sin datos
Andre Strydom	Member of Scientific Advisory Board	5.3yrs	sin datos	sin datos
Michelle Hastings	Member of Scientific Advisory Board	no data	sin datos	sin datos
Madge Shafmaster	Lead Independent Director	3.2yrs	US$40.00k	1.04% $ 214.5k
Carsten Korth	Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos

6.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de PMN se considera experimentada (6.7 años de antigüedad promedio).

ProMIS Neurosciences Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad